Atomo Diagnostics

Atomo Diagnostics is a medical technology company bringing next generation rapid diagnostic solutions to market and radically changing the way that we diagnose disease. AtomoRapid has launched in Africa and the UK, and USA market entry is underway.

Location Leichhardt NSW

Brands

Image for AtomoRapid HIV

AtomoRapid HIV

Given the impact that HIV continues to have on populations globally, Atomo has d…

AtomoRapid HIV

Supplied by Atomo Diagnostics

Given the impact that HIV continues to have on populations globally, Atomo has developed AtomoRapid HIV.

AtomoRapid HIV’s innovative design and ease of use offer significant advantages over conventional in-field test kits. These contain multiple components that are often difficult to use.

Using a WHO pre-qualified, antibody test for the detection of HIV 1&2 in human whole blood, serum or plasma it is a highly sensitive screening test that performs well when deployed in the field.

Image for AtomoRapid Malaria

AtomoRapid Malaria

In many areas in the developing world, especially in Africa – Malaria is a…

AtomoRapid Malaria

Supplied by Atomo Diagnostics

In many areas in the developing world, especially in Africa – Malaria is a more devastating disease than HIV/Aids, with the death toll highest amongst African children.

AtomoRapid Malaria is the world’s first integrated rapid malaria test. It was developed to improve ease of use and efficacy of in-field testing for malaria.

AtomoRapid Malaria is a Pf/PAN test for the qualitative detection of Plasmodium falciparum (P.f.), Plasmodium vivax (P.v), Plamodium ovale (P.o.), Plasmodium malarie (P.m) antigens in whole blood.

Using both pLDH and HRP2 technologies, the test is highly sensitive in accordance with WHO Standards and its convenient, integrated design makes self-testing easy and reliable in remote settings.

Image for AtomoRapid OEM

AtomoRapid OEM

The AtomoRapid platform is ideally suited to improve performance, addressing the…

AtomoRapid OEM

Supplied by Atomo Diagnostics

The AtomoRapid platform is ideally suited to improve performance, addressing the current limitations of lateral flow blood testing. We are able to offer AtomoRapid to leading diagnostic companies interested in converting their rapid tests onto this revolutionary rapid test platform.

Our platform will enable all companies with rapid tests on the market to now ensure that their current tests excel in a market that is increasingly focused on usability and convenience.

Markets

Current export locations:

  • Africa (Southern and East)
    • Botswana
    • Mauritius
    • Namibia
    • South Africa
    • Zambia

Regions we are wishing to develop export opportunities within:

  • Entire region
    • Africa (Central and West)
    • Africa (North)
    • Africa (Southern and East)
    • Asia (Central)
    • Asia (Mainland South-East)
    • Europe (Eastern)
    • Europe (South Eastern)
    • Europe (Southern)
    • Europe (Western)
    • Ireland
    • New Zealand
  • America (Central)
    • Costa Rica
    • Mexico
  • America (Northern)
    • United States of America
  • America (South)
    • Brazil
    • Chile
    • Ecuador
    • Uruguay
    • Venezuela
  • Asia (Chinese) (includes Mongolia)
    • China
    • Hong Kong (SAR of China)
  • Asia (Maritime South-East)
    • Indonesia
    • Malaysia
    • Philippines
    • Singapore
  • Asia (Southern)
    • Bangladesh
    • India
    • Nepal
    • Pakistan
  • Japan and the Koreas
    • Japan
    • Korea, Republic of (South)
  • Melanesia
    • Papua New Guinea
  • Middle East
    • Bahrain
    • Israel
    • Jordan
    • Kuwait
    • Lebanon
    • Oman
    • Qatar
    • Saudi Arabia
    • Turkey
    • United Arab Emirates
    • Yemen
  • United Kingdom & Channel Islands
    • United Kingdom

Contact

Contact image
Byron Darroch
Director, Business Development

Consider calling during business hours - it is 5:22am on Monday in New South Wales.